128 related articles for article (PubMed ID: 12641867)
1. Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment.
Herold M; Hieke K
Value Health; 2003; 6(2):167-74. PubMed ID: 12641867
[TBL] [Abstract][Full Text] [Related]
2. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
Sweetenham J; Hieke K; Kerrigan M; Howard P; Smartt PF; McIntyre AM; Townshend S
Br J Haematol; 1999 Jul; 106(1):47-54. PubMed ID: 10444162
[TBL] [Abstract][Full Text] [Related]
3. Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine.
Herold M; Hieke K
Eur J Health Econ; 2002; 3(3):166-72. PubMed ID: 15609141
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
[TBL] [Abstract][Full Text] [Related]
5. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
6. Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study.
Hutchinson J; Lloyd A; Gray A; Gale R; Hancock B
Acta Haematol; 2006; 115(1-2):28-34. PubMed ID: 16424646
[TBL] [Abstract][Full Text] [Related]
7. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use.
Herold M; Sacchi S; Hieke K
Haematologica; 2002 Jul; 87(7):719-29; discussion 729. PubMed ID: 12091123
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A
Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma.
Schmitz S; Aly F; Steinmetz T; Diehl V; Rehwald U
Onkologie; 2006 Jun; 29(6):258-64. PubMed ID: 16770087
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Evans SS; Gandhi AS; Clemmons AB; DeRemer DL
J Pharm Pract; 2017 Aug; 30(4):400-405. PubMed ID: 27432462
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F
Value Health; 2005; 8(4):462-70. PubMed ID: 16091023
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma.
van Agthoven M; Faber LM; Uyl-de Groot CA; Sonneveld P; Verdonck LF; Willemze R; Kluin-Nelemans JC; Löwenberg B; Huijgens PC
Eur J Haematol; 2002 Oct; 69(4):213-20. PubMed ID: 12431240
[TBL] [Abstract][Full Text] [Related]
13. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
[TBL] [Abstract][Full Text] [Related]
14. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
15. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):300-3. PubMed ID: 8674007
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET.
Moulin-Romsee G; Spaepen K; Stroobants S; Mortelmans L
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1074-80. PubMed ID: 18219485
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center.
Lee RC; Zou D; Demetrick DJ; Difrancesco LM; Fassbender K; Stewart D
Value Health; 2008; 11(2):221-30. PubMed ID: 18380634
[TBL] [Abstract][Full Text] [Related]
18. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R
J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
[TBL] [Abstract][Full Text] [Related]
20. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
Dranitsaris G; Altmayer C; Quirt I
Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
